Clinical trial NCT06171490: Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)
Official title: A Multi-center, Randomized, Controlled, Partially Blinded Study to Assess the Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of Nicotine Pouch 2.0 (NP2), 4mg and 6mg, Compared to Nicotine Lozenge 4mg and Nicotine Gum 4mg in Adult Cigarette Smokers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Use
Keywords: Nicotine
Nicotine-containing products
Tobacco
Pharmacokinetics
Lead sponsor: Philip Morris Products S.A.
Sponsor class: INDUSTRY
First posted: 2023-12-14
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The study will be conducted with 4 periods and 4 sequences in a Williams design (crossover).
Primary purpose: BASIC_SCIENCE

Brief summary: This is a multi-center, randomized, controlled, partially blinded study to assess the pharmacokinetics and comparative bioavailability of nicotine from two variants of NP2 (4 and 6 mg) in comparison with Loz-4mg and Gum-4mg in adult cigarette smokers. The subjects will be blinded to the randomized sequence and will be blinded to the variants of NP2 they will receive. The study will be conducted with 4 periods and 4 sequences in a Williams design (crossover).


Eligibility criteria: Inclusion Criteria:

* Subject has signed the ICF and is able to understand the information provided in the ICF.
* Subject has smoked on a daily basis for at least the last 18 months prior to the Screening visit.
* Subject has smoked on average ≥10 commercially available regular CIG/day over the last 4 weeks. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL).
* Subject is healthy as judged by the Investigator based on available assessments from the screening period (e.g., safety laboratory, spirometry, vital signs, physical examination, ECG, and medical history).

Exclusion Criteria:

* Subject has reasons other than medical (e.g., psychological, social reason) not to be part of the study, as determined by the Investigator.
* Subject is legally incompetent, or physically or mentally incapable of giving consent (e.g., emergency situation, under guardianship, prisoners).
* Subject has a clinically relevant disease which requires medication or any other medical condition including abnormal spirometry, safety laboratory, as determined by the Investigator.
* Subject presents difficulty with venipuncture and/or poor venous access.
* Subject has an oromucosal or dental condition, which may affect the use of the investigational products, as determined by the Investigator or subject has orthodontic braces and retention wire (could likely interfere with the gum dosing).
* Subject has medical conditions which require, or will require during the study, a medical intervention (e.g., start of treatment, surgery, hospitalization).
* Presence of fever (body temperature \>37.5°C) (e.g., a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
* Subject has a Hemoglobin level \< 11.0 g/dL for females and \< 12.0 g/dL for males at the Screening.
* Subject uses medication or any substance that aids in smoking cessation.
* Subject postponed the decision to quit using tobaccoor nicotine-containing products in order to participate in this study.
* Subject previously attempted to quit using tobacco- or nicotine-containing products within 28 days prior to the first study product administration.
* Subject has donated plasma within seven days prior to Screening or has donated or lost 450 mL or more of whole blood within 8 weeks prior to Screening for males, and in the 12 weeks prior to Screening for females.
* Subject has a known sensitivity or allergy to any of the investigational products, or ingredients.
* Subject has a positive serology test for HIV 1/2, Hepatitis B, Hepatitis C.
* Subject has a history of alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
* Subject has a positive urine drug test. Investigator will assess whether THC positive subjects are eligible for participation in the study.
* Subject has a positive alcohol breath test.
* Subject or one of their family members is a current or former employee of the tobacco industry.
* Subject or one of their family members a is an employee of the investigational site or of any other parties involved in the study.
* Subject has participated in another clinical study within 30 days prior to the Screening Visit or concomitantly participates in an investigational study involving no drug or device administration.
* Subject has been previously screened or enrolled in this study (except alternate subjects).
* For women only: subject is pregnant (does not have negative pregnancy tests at Screening Visit and at Admission) or is a lactating female.
* For women of childbearing potential only: subject does not agree to use an acceptable method of effective contraception.

Primary outcomes:
measure: Maximum Plasma Concentration [Cmax]
timeFrame: Measured from start of product use to 24 hours
measure: Area under the observed concentration-time curve (AUC) from start of product use (T0) to timepoint of last quantifiable concentration [AUC0-last] and extrapolated to infinity [AUC0-infinity]
timeFrame: Measured from start of product use (T0) to 2 minutes, to 4 minutes, to 10 hours, to time of last quantifiable concentration.
measure: Ratio of [AUC0-last] and [AUC0-infinity]
timeFrame: Measured from start of product use to 24 hours
measure: Time to the observed maximum concentration [Tmax]
timeFrame: Measured from start of product use to 24 hours
measure: Elimination rate constant [kel]
timeFrame: Measured from start of product use to 24 hours
measure: Half-life of nicotine [t1/2]
timeFrame: Measured from start of product use to 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Pharma Medica Research Inc.
state: Ontario
city: Québec
country: Canada
facility: Syneos Health Clinique Inc.
Study officials:
affiliation: Philip Morris Products S.A.
name: Christelle Haziza, PhD
role: STUDY_CHAIR
References: